PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
Pharmacokinetic/Pharmacodynamic Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
University of Bologna
120 participants
Jul 9, 2024
OBSERVATIONAL
Conditions
Summary
A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime/avibactam (CAZ/AVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime/avibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.
Eligibility
Inclusion Criteria4
- Patients with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ/AVI alone, CEF alone, CAZ/AVI plus FOS, or CEF plus FOS (any age)
- Signature of the informed consent (for pediatric patients: parents or guardians able to provide consent)
- Age ≥18 years
- Signature of the informed consent
Exclusion Criteria4
- Premature newborns
- Polymicrobial/mixed infections with the exception of cases with multiple Gram-negative bacteria susceptible to study drugs
- Continuous renal replacement therapy (CRRT) applications
- \- Any known clinically relevant health problems
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06651047